251 results on '"Carcas, A. J."'
Search Results
2. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
3. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)
4. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
5. No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
6. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
7. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery
8. ALDRESS: A Retrospective Pilot Study to Develop a Pharmacological Causality Algorithm for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
9. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
10. Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains
11. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population
12. Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data
13. Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity
14. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial
15. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population
16. Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units.
17. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain
18. Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand?
19. Who is willing to participate in low-risk pragmatic clinical trials without consent?
20. Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)
21. No changes in haemostasis after COVID-19-heterologous vaccination schedule: a sub analysis of the phase 2 CombiVacS study
22. A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
23. Public preferences on written informed consent for low‐risk pragmatic clinical trials in Spain
24. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital
25. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment
26. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment
27. Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial
28. Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study
29. Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study
30. Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study
31. A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
32. Non-Chemotherapy-Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital
33. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers
34. CYP2C9 polymorphism in five autochthonous population of the same geographic area (Spanish Pyrenees)
35. Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals
36. Use of antifungal agents in pediatric and adult high-risk areas
37. Additional file 2 of A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
38. Additional file 1 of A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
39. Additional file 3 of A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
40. The importance of sample size, log-mean ratios, and intrasubject variability in the acceptance criteria of 108 bioequivalence studies
41. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
42. Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 Patients
43. Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial
44. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score
45. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score
46. Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers
47. Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS)
48. Comparative Bioavailability of Two Oral 875/125mg Sachet Formulations of Amoxicillin/Clavulanic Acid in Healthy Volunteers
49. A MODEL-BASED COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL PHARMACOGENOMIC TESTING: 04
50. EFFICIENCY AND EFFECTIVENESS OF THE USE OF AN ACENOCUMAROL PHARMACOGENETIC DOSING ALGORITHM VS. USUAL CARE EN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE (VTD) INITIATING ORAL ANTICOAGULATION: STUDY PROTOCOL FOR A MULTICENTRIC RANDOMIZED CONTROLLED TRIAL: 06
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.